AIRLINK 154.89 Decreased By ▼ -5.39 (-3.36%)
BOP 9.14 Decreased By ▼ -0.34 (-3.59%)
CNERGY 7.47 Decreased By ▼ -0.34 (-4.35%)
CPHL 82.50 Decreased By ▼ -3.61 (-4.19%)
FCCL 42.65 Decreased By ▼ -1.08 (-2.47%)
FFL 14.46 Decreased By ▼ -0.50 (-3.34%)
FLYNG 28.12 Decreased By ▼ -0.57 (-1.99%)
HUBC 133.88 Decreased By ▼ -3.24 (-2.36%)
HUMNL 11.99 Decreased By ▼ -0.46 (-3.69%)
KEL 4.02 Decreased By ▼ -0.09 (-2.19%)
KOSM 5.10 Decreased By ▼ -0.14 (-2.67%)
MLCF 66.74 Decreased By ▼ -2.18 (-3.16%)
OGDC 200.90 Decreased By ▼ -6.91 (-3.33%)
PACE 5.06 Decreased By ▼ -0.10 (-1.94%)
PAEL 41.92 Decreased By ▼ -1.28 (-2.96%)
PIAHCLA 16.46 Decreased By ▼ -0.32 (-1.91%)
PIBTL 8.55 Decreased By ▼ -0.37 (-4.15%)
POWER 13.17 Decreased By ▼ -0.31 (-2.3%)
PPL 151.08 Decreased By ▼ -6.02 (-3.83%)
PRL 27.60 Decreased By ▼ -0.99 (-3.46%)
PTC 20.00 Decreased By ▼ -0.58 (-2.82%)
SEARL 80.80 Decreased By ▼ -3.79 (-4.48%)
SSGC 37.25 Decreased By ▼ -2.08 (-5.29%)
SYM 14.64 Decreased By ▼ -0.54 (-3.56%)
TELE 6.88 Decreased By ▼ -0.15 (-2.13%)
TPLP 8.50 Decreased By ▼ -0.32 (-3.63%)
TRG 64.25 Increased By ▲ 0.41 (0.64%)
WAVESAPP 8.59 Decreased By ▼ -0.28 (-3.16%)
WTL 1.24 Decreased By ▼ -0.02 (-1.59%)
YOUW 3.49 Decreased By ▼ -0.05 (-1.41%)
AIRLINK 154.89 Decreased By ▼ -5.39 (-3.36%)
BOP 9.14 Decreased By ▼ -0.34 (-3.59%)
CNERGY 7.47 Decreased By ▼ -0.34 (-4.35%)
CPHL 82.50 Decreased By ▼ -3.61 (-4.19%)
FCCL 42.65 Decreased By ▼ -1.08 (-2.47%)
FFL 14.46 Decreased By ▼ -0.50 (-3.34%)
FLYNG 28.12 Decreased By ▼ -0.57 (-1.99%)
HUBC 133.88 Decreased By ▼ -3.24 (-2.36%)
HUMNL 11.99 Decreased By ▼ -0.46 (-3.69%)
KEL 4.02 Decreased By ▼ -0.09 (-2.19%)
KOSM 5.10 Decreased By ▼ -0.14 (-2.67%)
MLCF 66.74 Decreased By ▼ -2.18 (-3.16%)
OGDC 200.90 Decreased By ▼ -6.91 (-3.33%)
PACE 5.06 Decreased By ▼ -0.10 (-1.94%)
PAEL 41.92 Decreased By ▼ -1.28 (-2.96%)
PIAHCLA 16.46 Decreased By ▼ -0.32 (-1.91%)
PIBTL 8.55 Decreased By ▼ -0.37 (-4.15%)
POWER 13.17 Decreased By ▼ -0.31 (-2.3%)
PPL 151.08 Decreased By ▼ -6.02 (-3.83%)
PRL 27.60 Decreased By ▼ -0.99 (-3.46%)
PTC 20.00 Decreased By ▼ -0.58 (-2.82%)
SEARL 80.80 Decreased By ▼ -3.79 (-4.48%)
SSGC 37.25 Decreased By ▼ -2.08 (-5.29%)
SYM 14.64 Decreased By ▼ -0.54 (-3.56%)
TELE 6.88 Decreased By ▼ -0.15 (-2.13%)
TPLP 8.50 Decreased By ▼ -0.32 (-3.63%)
TRG 64.25 Increased By ▲ 0.41 (0.64%)
WAVESAPP 8.59 Decreased By ▼ -0.28 (-3.16%)
WTL 1.24 Decreased By ▼ -0.02 (-1.59%)
YOUW 3.49 Decreased By ▼ -0.05 (-1.41%)
BR100 11,810 Decreased By -344.1 (-2.83%)
BR30 34,682 Decreased By -1185.3 (-3.3%)
KSE100 112,114 Decreased By -2757.7 (-2.4%)
KSE30 34,255 Decreased By -1011.9 (-2.87%)

Citi Pharma Limited (CPHL), a Pakistani pharmaceutical company, has commenced exports of nutraceuticals to the United States (US).

The company announced the development in its notice to the Pakistan Stock Exchange (PSX) on Friday.

“Citi Pharma, Pakistan’s largest API [Active Pharmaceutical Ingredients] manufacturer, is proud to announce this news as Pakistan’s first Nutraceutical products receive FDA [Food and Drug Administration] approval and formal ground launch in September 2024,” read the notice.

The listed company informed its stakeholders that the financial implications of the latest development are significant, “with the company expecting to generate approximately $3 million annually from this new revenue stream, alongside impressive profit margins of 25% to 30%”.

“This FDA approval not only boosts Citi Pharma’s credibility but also positions the company as a growing global player, potentially attracting further investment and international partnerships. “We have successfully received the payment of $109,500 for our first shipment,” it informed its stakeholders.

It is pertinent to mention that nutraceuticals are dietary supplements or food products containing active ingredients that provide specific health benefits beyond basic nutrition.

Meanwhile, Citi Pharma informed that the FDA has given its approval to categories including fertility, weight management, stress and mood booster, hair and skin care, and joint and muscle pains.

“This approval underscores Citi Pharma’s adherence to rigorous international quality standards, allowing the company to enter the highly competitive US market by exporting the finished nutraceutical products,” it added.

Earlier in July, Citi Pharma entered into a strategic partnership with India’s Murli Krishna Pharma Private Ltd (MKPL). Under the agreement, MKPL would supply APIs and products to Citi Pharma Limited in the Pakistani market.

Comments

Comments are closed.

Wasim Sep 20, 2024 06:44pm
This is one of the benefits of trade with India or is india using Pakistani company to gain access to US markets?
thumb_up Recommended (2)
Rashid Sep 21, 2024 08:53pm
Good
thumb_up Recommended (0)
Azher Sep 22, 2024 10:21am
Congratulations to entire CITI Pharma team for achieving a big mile stone
thumb_up Recommended (0)